ASCO 2024 | SURE-01/02: sacituzumab govitecan and pembrolizumab for MIBC
Antonio Cigliola, MD, IRCCS San Raffaele Hospital, Milan, Italy, discusses the findings from the SURE-01/02 trial (NCT05226117) investigating the antibody-drug conjugate (ADC) sacituzumab govitecan (SG) alone or in combination with pembroluzimab, for patients with muscle-invasive bladder cancer (MIBC). The study was carried out in patients who refused or were ineligible for cisplatin-based chemotherapy. A majority of patients completed four rounds of SG, and pathological complete response (pCR) was seen in nearly half of patients who did not receive a radical cystectomy. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
